The final days of the Trump administration were marked by the publication of a flurry of drug pricing regulations, among the most controversial of which was a regulation that would have purported to test a new most-favored-nations reimbursement mechanism for the top 50 physician-administered prescription medicines paid for under Medicare Part B.
Law360
How Drug Cos. Can Adapt To New Reference Pricing Rules
March 5, 2021
Contacts
Related Capabilities
SERVICES AND INDUSTRIES
Stay Up To Date